David A Gerber
Overview
Explore the profile of David A Gerber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Tan H, Gunawardena H, Cao J, Dang L, Deng H, et al.
J Tissue Eng
. 2025 Jan;
16:20417314251315523.
PMID: 39882546
Mural cells are essential for maintaining the proper functions of microvasculatures. However, a key challenge of microvascular tissue engineering is identifying a cellular source for mural cells. We showed that...
2.
Batra R, Latham S, Gerber D
Am J Bioeth
. 2024 Nov;
24(12):40-42.
PMID: 39565243
No abstract available.
3.
Abraham N, Gao Q, Kahan R, Alderete I, Wang B, Howell D, et al.
Transplant Direct
. 2024 May;
10(6):e1633.
PMID: 38807861
Background: Ex vivo kidney perfusion is an evolving platform that demonstrates promise in preserving and rehabilitating the kidney grafts. Despite this, there is little consensus on the optimal perfusion conditions....
4.
Iwai Y, Agala C, Gerber D
JAMA Netw Open
. 2024 Feb;
7(2):e240694.
PMID: 38421644
Importance: With the increasing prevalence of hepatocellular carcinoma (HCC), ablative therapy is a critical treatment option to achieve a cancer-free state. The anatomic location of the tumor can be a...
5.
Moon A, Cook S, Swier R, Sanoff H, Kappelman M, Wagner L, et al.
Hepatol Commun
. 2023 Nov;
7(11).
PMID: 37930127
Background: Patient-reported outcomes (PRO) measures relevant to domains most important to patients with HCC who received locoregional therapies are needed to advance patient-centered research. Furthermore, electronic PRO monitoring in clinical...
6.
Yi X, Xie Y, Gerber D
Biochem Biophys Res Commun
. 2023 Nov;
686:149200.
PMID: 37926045
Stem/progenitor cell therapy is a promising treatment option for patients with type 1 diabetes (T1D) a disease characterized by autoimmune destruction of pancreatic β cells. Actively injecting cells into an...
7.
Long J, Motter J, Jackson K, Chen J, Orandi B, Montgomery R, et al.
Am J Transplant
. 2023 Sep;
23(12):1980-1989.
PMID: 37748554
Older compatible living donor kidney transplant (CLDKT) recipients have higher mortality and death-censored graft failure (DCGF) compared to younger recipients. These risks may be amplified in older incompatible living donor...
8.
Moon A, Yanagihara T, Tepper J, Gerber D
Hepatol Commun
. 2023 Sep;
7(10).
PMID: 37708458
No abstract available.
9.
Moon A, Kim H, Singal A, Owen D, Mendiratta-Lala M, Parikh N, et al.
Hepatol Commun
. 2023 Jun;
7(7).
PMID: 37314737
Background Aims: Early-stage HCC can be treated with thermal ablation or stereotactic body radiation therapy (SBRT). We retrospectively compared local progression, mortality, and toxicity among patients with HCC treated with...
10.
Kumar A, Naso C, Bacon D, Agala C, Gerber D
Clin Transplant
. 2022 Dec;
37(3):e14878.
PMID: 36507574
Background: Several studies show an increase in complications, both cardiac and non-cardiac, and a higher mortality in patients with preexisting cardiac disease when they undergo elective surgery. Due to the...